The followingrepresents clinical trials available to our patients at the present time.

THE FOLLOWING IS THE LISTS OF SOME OF THE CLINICAL TRIALS AVAILABLE TO OUR PATIENTS AT THE PRESENT TIME.

COLORECTAL:

STAGE IV AMGEN
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY TO COMPARE THE EFFICACY OF PANITUMUMAB IN COMBINATION WITH MFOLFOX6 TO THE EFFICACY OF BEVACIZUMAB IN COMBINATION WITH MFOLFOX6 IN PATIENTS PREVIOUSLY UNTREATED, KRAS WILD-TYPE, UNRESECTABLE, METASTATIC COLORECTAL CANCER. PANITUMUMAB PROVIDED

STAGE IV ENZON
EZN-2208-04: A PHASE 2 STUDY OF EZN-2208 (PEG-SN38) ADMINISTERED WITH OR WITHOUT CETUXIMAB IN PATIENTS WITH MCRC PREVIOUSLY TREATED WITH 5-FU, OXALIPLATIN & IRINOTECAN. MUTATED KRAS ARE TREATED WITH EZN-2208 AND KRAS WILD-TYPE ARE EZN-2208 + CETUXIMAB VS IRINOTECAN + CETUXIMAB EZN-2208 PROVIDED

LUNG:
STAGE IV DR. CHANDRA BELANI:
OPEN-LABEL, RANDOMIZED FIRST-LINE TREATMENT OF DOCETAXEL,CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY BEVACIZUMAB MAINTENANCE THEN BEVACIZUMAB PLUS PEMETREXED VS PEMETREXED ALONE AS SECOND LINE TREATMENT FOR STAGE IIIB OR IV NSCLC.
AVASTIN PROVIDED

STAGE IV ACORN
A RANDOMIZED PHASE 2B STUDY OF CETUXIMAB (ERBITUX) IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) CETUXIMAB PROVIDED

LYMPHOMA

STAGE IV GENENTECH
OPEN-LABEL STUDY OF FASTER INFUSION TIME OF RITUXAN IS PREVIOULSY UNTREATED DIFFUSE LARGE B-CELL OR FOLLICULAR NON-HODGKIN’S LYMPHOMA

STAGE IV MILLENIUM
TWO-ARM NON-RANDOMIZED TRIAL OF VELCADE IN COMBINATION WITH RITUXIMAB, CYCLOPHOSAMIDE AND PREDNISONE WITH OR WITHOUT DOXIRUBICIN FOLLOWED BY RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA. VELCADE PROVIDED

LYMPHOMA

STAGE IV CEPHALON
AN OPEN-LABEL STUDY OF BENDAMUSTINE HYDROCHLORIDE IN COMBINATION WITH RITUXIMAB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA.
BENDAMUSTINE HCL PROVIDED.

MISCELLANEOUS

AMGEN
A OPEN LABEL STUDY OF NPLATE FOR SUBJECTS WITH SEVERE THROMBOCYTOPENIA PURPURA DUE TO MDS. NPLATE PROVIDED

AMGEN
A PROSPECTIVE, PHASE IV, OPEN-LABEL STUDY EVALUATING CHANGES IN BONE MARROW MORPHOLOGY IN ADULT SUBJECTS RECEIVING ROMIPLOSTIM FOR THE TREATMENT OF THROMBOCYTOPENIA ASSOCIATED WITH IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA PURPURA (ITP) NPLATE PROVIDED

LUITPOLD
A MULTICENTER, RANDOMIZED, ACTIVE CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF INTRAVENOUS FERRIC CARBOXYMALTOSE (FCM) IN PATIENTS WITH IRON DEFICIENCY ANEMIA (IDA).
FCM, ORAL IRON TABLETS & VENOFER WILL BE PROVIDED

MULTIPLE MYELOMA

MILLENNIUM
OPEN-LABEL, RANDOMIZED 3-ARM COMPARATIVE STUDY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA IN PTS.NOT ELIGIBLE FOR HIGH DOSE CHEMOTHERAPY OR STEM CELL TRANSPLANTATION.
VELCADE AND THALIDOMIDE PROVIDED.

OBSERVATIONAL STUDIES

MORE REGISTRY: IN IRON OVERLOADED LOWER-RIDK MDS PATIENTS.
ARIES STUDY: AVASTIN REGISTRY REGARDING EFFECTIVENESS IN NSCL.
THE NATIONAL LYMPHOCARE STUDY: FOLLICULAR NHL

VIRGO STUDY: TREATMENT PATTERNS AND SAFETY OUTCOMES FOR METASTATIC OR LOCALLY RECURRENT BREAST CANCER. BLOOD TESTS AND ARCHIVAL TISSUE SPECIMEN REQUIRED.

PROMETHEUS: PROGNOSTIC UTILITY OF ACTIVATED TUMOR MARKERS IN CIRCULATING TUMOR CELLS IN WOMEN WITH METASTATIC BREAST CANCER.